To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

And more pharma news updates from Pharmalittle.

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

Analysts expect the positive outcome to support Eisai, the Japan-based pharmaceutical company behind lecanemab, as it works to bring the drug to market. Eisai is co-developing lecanemab with Biogen, ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Japanese drugmaker Eisai (TYO: 4523) today announced that the in-house-discovered and developed orexin receptor antagonist Dayvigo (lemborexant) has been approved in China for the treatment of adults ...

Japanese pharmaceutical company Eisai has announced it is expanding into Russia, by establishing a new sales and marketing operation in Moscow. Eisai’s market entry will be based on launching ...